 FDA Accepted IND Filing for the company to initiate a phase 2b study using KPI-012 for the treatment of patients with the persistent corneal epithelial defect. The phase 2b study, using KPI-012 for the treatment of patients with a persistent corneal epithelial defect, is expected to begin in Q1 of 2023. 